Cleveland BioLabs to Present Protectan CBLB502 at 2008 BARDA Day ...
Cleveland BioLabs to Present Protectan CBLB502 at 2008 BARDA Day. - BUFFALO, NY--(MARKET WIRE)--Sep 23, 2008 -- Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) ...Cleveland BioLabs Protectan CBLB612 Demonstrates Significant Reduction ...
Cleveland BioLabs Protectan CBLB612 Demonstrates Significant Reduction of Myelosuppression in Mouse Model of Chemotherapy. - BUFFALO, NY--(MARKET WIRE)--Oct 27, ....::: Cleveland BioLabs, Inc :::.
Protectan CBLB502 is being developed under the FDA's animal efficacy rule to ... BioLabs has successfully established cGMP quality manufacturing for Protectan ...Cleveland BioLabs and Cleveland Clinic Demonstrate Accelerated Recovery ...
BUFFALO, NY, Aug 13 (MARKET WIRE) -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) and founding partner Cleveland Clinic reported today that CBLI's lead product, Protectan ...CBLI CBLI: Awarded $13.3M DHHS Contract for Development of Protectan ...
TradingMarkets News for CBLI - CBLI: Awarded $13.3M DHHS Contract for Development of Protectan CBLB502 ... Protectan CBLB502 is a derivative of a microbial ...Cleveland BioLabs Doses First Healthy Volunteer In Initial Safety Study For...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that on October 14, the first healthy volunteer was dosed in the initial human safety study for Protectan CBLB502, ...